welcomes you to the new, improved website!The STICH trial compares medical therapy to medical therapy + CABG for ischemic cardiomyopathy. In this study of over 1,200 there were 462 deaths during a median f/u period of nearly 5 years. CABG reduced the risk of sudden death and death due to pump failure; overall cardiovascular death was reduced by CABG but not significantly (p=0.09). There was a substantial early increase in mortality in pts undergoing CABG; the protective effects of CABG were evident primarily after 2 years.
Surgical Treatment for Ischemic Heart Failure (STICH) Trial
Submitted by: Erica Curcio
Source: JACC Heart Failure
Keywords:
Author(s): Peter Carson; John Wertheimer; Alan Miller; Christopher M. O’Connor; Ileana L. Pina; Craig Selzman; Carla Sueta; Lilin She; Deborah Greene; Kerry L. Lee; Robert H. Jones; Eric J. Velazquez